Ly93, an Oral Active SMS2 Inhibitor, Has Anti-Atherosclerotic Activity
The sphingomyelin synthase 2 (SMS2) is a potential target for pharmacological intervention in atherosclerosis. However, as far as now, reports about selective SMS2 inhibitors and their pharmacological activities were lacked….